Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma

Table 2 Univariate analysis of overall survival (OS) and recurrence-free survival (RFS) of the 285 HCC patients

Variable	Number of patients	OS (months)	P	RFS (months)	P
Age			0.879		0.921
<65 years	238	79.4 ± 4.6		72.4 ± 4.6
≥65 years	47	77.9 ± 8.6		73.4 ± 9.4
Sex			0.163		0.141
Male	262	83.0 ± 4.3		76.4 ± 4.2
Female	23	54.0 ± 7.2		47.5 ± 8.1
Cirrhosis			0.911		0.806
Yes	250	80.4 ± 4.4		73.7 ± 4.3
No	35	67.6 ± 8.3		64.1 ± 8.8
Treatment allocation			*0.012*		*0.004*
Combination^a	137	91.2 ± 6.1		84.1 ± 6.0
Surgery	148	61.7 ± 3.8		57.1 ± 4.3
Tumor number			*<0.001*		*<0.001*
1	128	80.4 ± 5.0		66.7 ± 3.9
2	93	73.3 ± 6.8		69.8 ± 7.2
3	49	82.2 ± 9.5		75.3 ± 8.6
4	15	31.8 ± 10.0		26.6 ± 7.7
CA19-9			0.088		0.093
Positive	113	71.0 ± 5.8		68.0 ± 6.1
Negative	172	84.1 ± 5.5		74.1 ± 4.9
Alpha fetoprotein			*0.004*		*0.002*
≥400 ng/mL	79	60.6 ± 6.7		56.6 ± 7.1
<400 ng/mL	206	87.2 ± 4.8		79.2 ± 4.5
Albumin			*0.003*		*0.014*
≥40 g/L	174	87.4 ± 5.4		76.8 ± 4.9
<40 g/L	111	65.3 ± 5.9		62.5 ± 6.2
Prothrombin time			*0.018*		*0.011*
≤13.5 s	217	85.0 ± 4.9		78.2 ± 4.8
>13.5 s	68	63.0 ± 6.8		58.2 ± 7.4
Platelet count			0.417		0.604
≥100 × 10⁹/L	200	82.5 ± 4.9		74.0 ± 4.6
<100 × 10⁹/L	85	72.1 ± 6.9		9.0 ± 7.5
Hemoglobin			0.456		0.239
≥120 × 10¹²/L	247	81.6 ± 4.4		75.5 ± 4.2
<120 × 10¹²/L	38	67.9 ± 9.3		51.6 ± 7.9
Maximal tumor size			*0.009*		*0.004*
≤3 cm	130	95.0 ± 5.4		88.2 ± 5.3
>3 cm	155	65.8 ± 4.8		56.1 ± 4.3
Hypersplenism			0.941		0.668
Yes	144	79.4 ± 6.2		73.6 ± 5.9
No	141	76.0 ± 5.0		71.8 ± 5.4

All values are presented as mean ± standard deviation. ^aCombination treatment includes ablation and hepatectomy.

ISSN: 2523-3548